New Elite Feature: Chart Magnifying Glass

AC Immune SA

Contributing Author

Recent Articles by AC Immune SA

Jun-11	AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease ACIU +6.60% GlobeNewswire
May-22	AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS ACIU GlobeNewswire
May-12	AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM ACIU GlobeNewswire
Apr-30	AC Immune First Quarter 2026 Financial and Corporate Updates ACIU GlobeNewswire
Apr-30	AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease ACIU GlobeNewswire
Apr-07	AC Immune Announces Amendment to Morphomer Tau License and Collaboration Agreement with Lilly ACIU +15.19% GlobeNewswire
Mar-19	AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 ACIU GlobeNewswire
Mar-13	AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update ACIU GlobeNewswire
Mar-05	AC Immune Announces Upcoming Industry Symposium on Parkinson's Disease and Presentation at AD/PD 2026 ACIU GlobeNewswire
Feb-24	AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor ACIU +7.51% GlobeNewswire
Dec-11	AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease ACIU +15.41% GlobeNewswire
Nov-11	AC Immune to Present at the Jefferies 2025 London Healthcare Conference ACIU GlobeNewswire
Nov-04	AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update ACIU GlobeNewswire
Oct-28	AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board ACIU GlobeNewswire
Oct-24	First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine ACIU +15.66% GlobeNewswire
Sep-25	Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine ACIU +6.59% GlobeNewswire
Sep-04	AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway ACIU GlobeNewswire
Aug-05	AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update ACIU +11.62% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)